Product Profile
no_image no_image no_image no_image no_image no_image no_image no_image
PRODUCTS DISEASE PHARMACOVIGILANCE MEDCAL
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
GEMCIKAL
GEMCIKAL
GEMCIKAL

GEMCIKAL

BRANDED
Mechanism of action: inhibition of DNA synthesis, metabolized intracellularly to produce 2 active metabolites.
Available at :
Share this article
Related Articles
34627118e8c408cdf4fd408bc5c8fc26.JPG
Serplulimab Approved for First-line Treatment of Extensive Stage Small Cell Lung Cancer (ES-SCLC) in the European Union
by dr. Dita Arccinirmala | 06 Feb 2025
5dc30f9a305a3bb238cfb31b6d0cbc84.jpg
ASCO Recommendations Regarding Diet and Exercise for Cancer Patients
by Dr. Dedyanto Henky Saputro, M. Gizi, AIFO-K | 17 Jun 2022
1a635c51a5e289b4bd1a14ac1dde1c8b.jpg
TPC Induction Chemotherapy for Advanced Locoregional Nasopharyngeal Cancer Patients
by dr. Hastarita Lawrenti | 12 Apr 2022
3db3599499024bf17bf39d3cdeb1a2e2.jpg
Asciminib or Bosutinib in CML Patients with ≥ 2 Previous TKI
by Dr. Hastarita | 21 Dec 2021
7a6500e600f953367a3895df1e1d3e8c.jpg
Asciminib FDA Approved for Chronic Myeloid Leukemia Philadelphia Chronic Positive and T315I Mutation
by dr. Hastarita Lawrenti | 12 Nov 2021